Horizon Pharma PLC (HZNP) Stock Rating Lowered by ValuEngine

ValuEngine downgraded shares of Horizon Pharma PLC (NASDAQ:HZNP) from a buy rating to a hold rating in a research report report published on Friday, September 1st.

A number of other research analysts also recently weighed in on HZNP. BMO Capital Markets restated a buy rating and set a $17.00 price target (down previously from $24.00) on shares of Horizon Pharma PLC in a report on Tuesday, May 9th. Mizuho downgraded shares of Horizon Pharma PLC from a buy rating to a neutral rating and dropped their target price for the stock from $22.00 to $10.00 in a report on Tuesday, May 9th. Cowen and Company set a $20.00 target price on shares of Horizon Pharma PLC and gave the stock an outperform rating in a report on Tuesday, May 9th. Stifel Nicolaus reiterated a buy rating and issued a $20.00 target price (down previously from $35.00) on shares of Horizon Pharma PLC in a report on Tuesday, May 9th. Finally, Jefferies Group LLC set a $14.00 price target on shares of Horizon Pharma PLC and gave the stock a buy rating in a research report on Tuesday, May 9th. Five research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $18.67.

Shares of Horizon Pharma PLC (NASDAQ HZNP) opened at 12.11 on Friday. Horizon Pharma PLC has a 12-month low of $9.45 and a 12-month high of $21.98. The company has a 50 day moving average price of $12.81 and a 200 day moving average price of $13.04. The firm’s market cap is $1.98 billion.

Horizon Pharma PLC (NASDAQ:HZNP) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.29. The business had revenue of $289.51 million for the quarter, compared to the consensus estimate of $237.01 million. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%. Horizon Pharma PLC’s revenue for the quarter was up 12.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.56 EPS. On average, analysts forecast that Horizon Pharma PLC will post $1.08 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Horizon Pharma PLC (HZNP) Stock Rating Lowered by ValuEngine” was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://ledgergazette.com/2017/09/17/horizon-pharma-plc-hznp-lowered-to-hold-at-valuengine.html.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Profund Advisors LLC grew its holdings in Horizon Pharma PLC by 0.8% during the first quarter. Profund Advisors LLC now owns 13,508 shares of the biopharmaceutical company’s stock valued at $200,000 after purchasing an additional 112 shares during the period. First Mercantile Trust Co. boosted its holdings in shares of Horizon Pharma PLC by 2.7% in the first quarter. First Mercantile Trust Co. now owns 11,770 shares of the biopharmaceutical company’s stock valued at $174,000 after buying an additional 310 shares during the period. US Bancorp DE boosted its holdings in shares of Horizon Pharma PLC by 1.2% in the first quarter. US Bancorp DE now owns 32,050 shares of the biopharmaceutical company’s stock valued at $473,000 after buying an additional 368 shares during the period. Prudential Financial Inc. boosted its holdings in shares of Horizon Pharma PLC by 2.6% in the first quarter. Prudential Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 420 shares during the period. Finally, Sheaff Brock Investment Advisors LLC raised its position in Horizon Pharma PLC by 5.0% during the second quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock worth $125,000 after acquiring an additional 500 shares in the last quarter. Hedge funds and other institutional investors own 82.30% of the company’s stock.

About Horizon Pharma PLC

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply